Laboratory monitoring of anticoagulant medications: Focus on novel oral anticoagulants

Postgraduate Medicine

Volumn 125, Issue 2, 2013, Pages 135-145

  Baruch, Lawrence ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apixaban; Coagulation assays; Dabigatran; Edoxaban; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; EDOXABAN; HEPARIN; NEW DRUG; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ACTIVATED CLOTTING TIME; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DOSE RESPONSE; DRUG CLASSIFICATION; ECARIN CHROMOGENIC ASSAY; HUMAN; LABORATORY TEST; LOW DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; RELIABILITY; STANDARDIZATION; THROMBIN TIME; VALIDATION STUDY;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION TESTS; DRUG MONITORING; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; THROMBOSIS;

EID: 84876750186     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2013.03.2647     Document Type: Article

References (73)

1. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012. http://www.xareltohcp.com/sites/default/files/shared/xarelto_0.pdf#zoom=100. Accessed April 23, 2012.
2. Eliquis [package insert]. Uxbridge, UK: Bristol-Myers Squibb/Pfizer EEIG; 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed October 25, 2011.
3. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012. http://bidocs.boehringer-ingelheim.com/BIWebAc-cess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed February 7, 2012.
4. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.
5. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.
6. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-753.
7. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
8. Marlar RA, Gausman JN. Do you report an accurate international normalized ratio? Find out using local verification and calibration. Lab Medicine. 2011;42(3):176-181.
9. Marlar RA, Cook J, Johnston M, et al. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline. 2nd ed. CLSI document H47-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
10. Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2(6):849-860.
11. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):160S-198S.
12. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e44S-e88S.
13. Poller L, Ibrahim S, Keown M, Pattison A, Jespersen J. The prothrombin time/international normalized ratio (PT/INR) line: derivation of local INR with commercial thromboplastins and coagulometers-two independent studies. J Thromb Haemost. 2011;9(1):140-148.
14. Fairweather RB, Ansell J, van den Besselaar AM, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med. 1998;122(9):768-781.
15. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122(9):782-798.
16. Dudek MM, Kent N, Gustafsson KM, Lindahl TL, Killard AJ. Fluorescence-based blood coagulation assay device for measuring activated partial thromboplastin time. Anal Chem. 2011;83(1):319-328.
17. Dudek MM, Harris LF, Killard AJ. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development. Int J Lab Hematol. 2011;33(3):272-280.
18. Perry D, Todd T. A practical guide to laboratory haemostasis: activated clotting time (ACT). 2011. http://www.practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/act.html. Accessed February 12, 2013.
19. Kostousov V. Activated clotting time. 2011. http://emedicine.medscape.com/article/2084818-overview#a30. Accessed February 12, 2013.
20. de Denus S, Spinler SA. Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy. 2002;22(4): 433-435.
21. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003;33(4): 173-183.
22. Choi TS, Khan AI, Greilich PE, Kroll MH. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery. Am J Clin Pathol. 2006;125(2):290-295.
23. Perry D, Todd T. A practical guide to laboratory haemostasis: ecarin clotting time. 2011. http://www.practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/ecarin_ct.html. Accessed February 12, 2013.
24. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay-a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2003;33(4):184-191.
25. Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. Thromb Res. 2008;123(1):159-165.
26. Guy S, Kitchen S, Laidlaw S, Cooper P, Woolley A, Maclean R. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. Br J Haematol. 2008;142(3):466-468.
27. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107(5):985-997.
28. Crookston K, Rosenbaum L, Gober-Wilcox J. PathologyOutlines.com. Coagulation. 2011. http://www.pathologyoutlines.com/coagulation.html#thrombintime. Accessed February 12, 2013.
29. Flanders MM, Crist R, Rodgers GM. Comparison of five thrombin time reagents. Clin Chem. 2003;49(1):169-172.
30. Robert S, Mullier F, Mekouar H, et al. Comparison of laboratory assays to measure rivaroxaban and dabigatran. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3332.
31. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138-143.
32. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98(1):234-242.
33. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137(4):572-574.
34. Perry D, Todd T. A practical guide to laboratory haemostasis: anti-Xa assays. 2011. http://www.practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/anti_xa_assays.html. Accessed February 12, 2013.
35. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799-807.
36. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus anti-factor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45(7-8): 861-868.
37. Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay [published online ahead of print October 14, 2011]. Am J Hematol.
38. Ignjatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res. 2007;120(3):347-351.
39. Yin ET, Rozin T. Heptest®-POC-Hi, a new simple one-step point of care (POC) anti-Xa clotting assay for monitoring heparin activity during cardiac surgery. J Thromb Haemost. 2005;3(suppl 1):Abstract P1882.
40. Abildgaard U, Norrheim L, Larsen AE, Nesvold A, Sandset PM, Odegaard OR. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay. Haemostasis. 1990;20(4):193-203.
41. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103(4):815-825.
42. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107(2):379-387.
43. Harenberg J, Kramer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32(3):267-271.
44. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263-1271.
45. Korte W, Jovic R, Hollenstein M, Degiacomi P, Gautschi M, Ferrandez A. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin. Hämostaseologie. 2010;30(4):212-216.
46. Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol. 2008;130(3):446-454.
47. Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost. 2007;33(05):503-507.
48. Perry D, Todd T. A practical guide to laboratory haemostasis: dilute Russell's viper venom time. 2011. http://www.practical-haemostasis.com/Thrombophilia%20Tests/APS/drvvt.html. Accessed April 10, 2012.
49. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res. 2008;123(2):396-403.
50. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2010;9(1):133-139.
51. Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007;45(4):237-243.
52. Raivio P, Kuitunen A, Petaja J, Ilveskero S, Lassila R. Monitoring high-dose heparinization during cardiopulmonary by-pass-a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Thromb Haemost. 2008;99(2):427-434.
53. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371-378.
54. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann Pharmacother. 2011;45(7-8): e40.
55. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127.
56. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012;125(4):417-420.
57. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-2175.
58. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419-1426.
59. US Food and Drug Administration. FDA Advisory Committee Briefing Document. Dabigatran. 2010. http://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/CardiovascularandRe-nalDrugsAdvisoryCommittee/UCM247244.pdf Accessed December 4, 2012.
60. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838-847.
61. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104(5):1078-1079.
62. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-686.
63. US Food and Drug Administration. Johnson and Johnson Pharmaceutical Research and Development. Advisory committee briefing document: rivaroxaban for the prevention of stroke and non-central nervous system (CNS) systemic embolism in patients with atrial fibrillation. 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270797.pdf Accessed December 4, 2012.
64. Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis. 2011;22(8):637-641.
65. US Food and Drug Administration. FDA draft briefing document for the cardiovascular and renal drugs committee (CRDAC). 2011. http://www. fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf Accessed April 17, 2012.
66. Zhao X, Sun P, Zhou Y, et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol. 2009;68(1):77-88.
67. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47(11):1398-1407.
68. Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011;105(2):385-386.
69. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors [published online ahead of print April 2, 2012]. Clin Appl Thromb Hemost.
70. Barrett YC, Wang J, Song Y, et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost. 2012;107(5):916-924.
71. He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129-139.
72. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32(2):183-187.
73. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012;129(4):e77-e82.